Skip to main content
. Author manuscript; available in PMC: 2009 Nov 17.
Published in final edited form as: J Immunol. 2008 Oct 1;181(7):5035–5044. doi: 10.4049/jimmunol.181.7.5035

FIGURE 3.

FIGURE 3

AnxA1-deficient mice exhibit increased susceptibility to DSS-induced acute colitis. AnxA1 (−/−) mice demonstrated a significantly higher weight loss compared with WT controls beginning at day 3 of DSS treatment (A; *, p-value <0.05, n = 7 mice). A sustained increase in the DAI in AnxA1 (−/−) mice compared with WT controls was observed on days 1–7 of DSS treatment (B; *, p-value <0.05, n = 7 mice). Rectal bleeding scores (C) were also increased in AnxA1 (−/−) animals compared with WT controls during DSS treatment (*, p-value <0.05, n = 7 mice). An increase in the colon weight/length ratio was observed in AnxA1 (−/−) mice compared with WT controls following 7 days of DSS administration (D; *, p-value <0.05, n = 7 mice).